98%
921
2 minutes
20
Henoch-Schonlein purpura nephritis (HSPN) is a common glomerulonephritis secondary to Henoch-Schonlein purpura (HSP) that affects systemic metabolism. Currently, there is a rarity of biomarkers to predict the progression of HSPN. This work sought to screen metabolic markers to predict the progression of HSPN via serum-urine matched metabolomics. A total of 90 HSPN patients were enrolled, including 46 HSPN (+) patients with severe kidney damage (persistent proteinuria >0.3 g/day) and 44 HSPN (-) patients without obvious symptoms (proteinuria < 0.3 g/day). Untargeted metabolomics was determined by liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-Q/TOF-MS). A total of 38 and 50 differential metabolites were, respectively, identified in serum and urine from the comparison between HSPN (+) and HSPN (-) patients. Altered metabolic pathways in HSPN (+) mainly included glycerophospholipid metabolism, pyruvate metabolism, and citrate cycle. A panel of choline and -vaccenic acid gave areas under the curve of 92.69% in serum and 72.43% in urine for differential diagnosis between HSPN (+) and HSPN (-). In addition, the two metabolites showed a significant association with clinical indices of HSPN. These results suggest that serum-urine matched metabolomics comprehensively characterized the metabolic differences between HSPN (+) and HSPN (-), and choline and -vaccenic acid could serve as biomarkers to predict HSPN progression.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149729 | PMC |
http://dx.doi.org/10.3389/fmed.2021.657073 | DOI Listing |
BMC Nephrol
August 2025
Tongji Medical College, Wuhan Children's Hospital, Huazhong University of Science & Technology, Xianggang Road 100, Wuhan, Hubei Province, 430014, China.
Background: Henoch-Schönlein purpura nephritis (HSPN) is the most severe manifestation of Henoch-Schönlein purpura, significantly impacting patient outcomes. While immunosuppressive therapies like cyclophosphamide (CTX) and mycophenolate mofetil (MMF) are commonly used, evidence regarding the efficacy and safety of tacrolimus (TAC) in HSPN remains limited. This study presents the first systematic review and meta-analysis specifically evaluating the efficacy and safety of tacrolimus (TAC) in treating Henoch-Schönlein purpura nephritis (HSPN), aiming to fill a critical gap in evidence for clinical decision-making.
View Article and Find Full Text PDFMedicine (Baltimore)
July 2025
Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China.
Background: This systematic review studied and compared the safety and efficacy of glucocorticoids (GCs) + cyclophosphamide (CTX) and GCs + tacrolimus (TAC) therapies for treating children with Henoch-Schönlein purpura nephritis (HSPN).
Methods: The data on GCs + CTX and GCs + TAC therapies for HSPN children were procured from the EMbase, China National Knowledge Infrastructure, the Cochrane Library, PubMed, and Wanfang from the inception to May 10, 2024.
Results: This review included 5 studies (2 non-randomized and 3 randomized controlled trials), comprising 363 patients.
Cureus
June 2025
Internal Medicine, Medical University of South Carolina, Charleston, USA.
Staphylococcal infections remain a prominent cause of hospital- and community-acquired infections in the United States. Glomerulonephritis with predominant Immunoglobulin A (IgA) deposition following staphylococcal infection has been described as IgA-dominant postinfectious glomerulonephritis (IgA-PIGN). This clinical entity can mimic Henoch-Schönlein purpura nephritis (HSPN) given that it may also be preceded by staphylococcal infection, have similar kidney biopsy findings, and present with similar signs and symptoms.
View Article and Find Full Text PDFAm J Med Sci
July 2025
Department of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Sichuan Clinical Research Center for Kidney Diseases, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan, China. Electronic address:
Background: The aim of this study is to investigate the clinicopathologic characteristics, treatment and prognosis of crescentic glomerulonephritis (Crescentic GN) in patients with normal renal function at diagnosis, and compare to those with impaired renal function.
Methods: We conducted a retrospective review of patients with renal biopsy proven Crescentic GN at our center and divided them into normal eGFR group (eGFR≥60 ml/min/1.73 m) and low eGFR group (eGFR <60 ml/min/1.
Front Public Health
May 2025
Department of Nephrology, Children's Hospital of Anhui Medical University, Children's Medical Center of Anhui Medical University, Hefei, Anhui, China.
Objective: The risk factors for Henoch-Schönlein purpura nephritis (HSPN) remain largely unclear, particularly in family environment and vaccination. This study aimed to develop a predictive framework to quantify the risk of HSPN by examining family environmental factors and COVID-19 vaccination outcomes in children with Henoch-Schönlein purpura (HSP) in Anhui, China.
Methods: This study retrospectively analyzed 362 children diagnosed with HSP at Anhui Children's Hospital between January 2020 and February 2024.